drugset
drugset / Trial / NCT04802863

Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects

NCT04802863 ↗

Phase 1 Completed 21 enrolled Evopoint Biosciences Inc.
NaSingle-groupOpen-labelBasic science

Summary

This is a Phase 1, open-label, single-center study of XNW4107 and imipenem/cilastatin administered intravenously.

Timeline

Start
2021-03-25
Primary completion
2021-05-15
Completion
2021-09-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cilastatin Small molecule 500 mg Intravenous
Subject IMIPENEM ANHYDROUS Small molecule 500 mg Intravenous
Subject funobactam Small molecule 250 mg Intravenous

Indications

bacterial infectious disease